Elosulfase alfa

VIMIZIM (elosulfase alfa) is an injectable enzyme replacement therapy used to treat Mucopolysaccharidosis Type IVA (Morquio A syndrome), a rare genetic disorder. It works by providing the missing enzyme to break down certain sugars in the body. Administered intravenously by a healthcare professional, it's available as a 5 mg/5 mL solution. Manufactured by BioMarin Pharmaceutical Inc. This information was generated using AI and is provided for informational and research purposes only.